Asgari Taei Afsaneh, Khodabakhsh Pariya, Nasoohi Sanaz, Farahmandfar Maryam, Dargahi Leila
Neuroscience Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Mol Neurobiol. 2022 Oct;59(10):6281-6306. doi: 10.1007/s12035-022-02967-4. Epub 2022 Aug 3.
It is well acknowledged that neuroprotective effects of transplanted mesenchymal stem cells (MSCs) in ischemic stroke are attributed to their paracrine-mediated actions or bystander effects rather than to cell replacement in infarcted areas. This therapeutic plasticity is due to MSCs' ability to secrete a broad range of bioactive molecules including growth factors, trophic factors, cytokines, chemokines, and extracellular vesicles, overall known as the secretome. The secretome derivatives, such as conditioned medium (CM) or purified extracellular vesicles (EVs), exert remarkable advantages over MSC transplantation in stroke treating. Here, in this review, we used published information to provide an overview on the secretome composition of MSCs, underlying mechanisms of therapeutic effects of MSCs, and preclinical studies on MSC-derived products application in stroke. Furthermore, we discussed current advantages and challenges for successful bench-to-bedside translation.
众所周知，缺血性中风中移植间充质干细胞（MSCs）的神经保护作用归因于其旁分泌介导的作用或旁观者效应，而非梗死区域的细胞替代。这种治疗可塑性源于MSCs分泌多种生物活性分子的能力，这些分子包括生长因子、营养因子、细胞因子、趋化因子和细胞外囊泡，统称为分泌组。分泌组衍生物，如条件培养基（CM）或纯化的细胞外囊泡（EVs），在中风治疗中比MSC移植具有显著优势。在此综述中，我们利用已发表的信息，概述了MSCs的分泌组组成、MSCs治疗作用的潜在机制以及MSCs衍生产品在中风中应用的临床前研究。此外，我们还讨论了成功实现从 bench 到 bedside 转化的当前优势和挑战。
